Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed patient.~* Provision of written informed consent.~* De Novo (primary) or Secondary AML.~* Not eligible for intensive induction chemotherapy because of medical, social or psychological reasons.~Exclusion Criteria:~* Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL).~* Patients with blast crisis of chronic myeloid leukaemia.~* Persistent, chronic, clinically significant toxicities from any prior anti- cancer therapy greater than CTCAE Grade 1 (except alopecia).

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): AZD1152 variable dose in combination with 20 mg of LDAC. (The LDAC is given twice daily.)

Based on this trial design, predict the completion outcome and termination type (if applicable).